Tara Dougal, event director for pharma at Informa Markets and head of CPHI Milan, previews the 2026 show in an interview with ...
Extending CAR T beyond cancer alters risk–benefit calculus, because chronic autoimmune populations have alternative therapies ...
David S. Thompson, CSAP, is Chief Alliance Officer at Eli Lilly and Company.
Novartis obtained portfolio-level options for exclusive rights to Hybrozyme-enabled SC formulations, with economics up to ...
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor. PhD, AbbVie, and Swita Singh, PhD, Bristol ...
On August 31, 2026, Eli Lilly announced it has entered a definitive agreement to acquire Merida Biosciences, a biotechnology ...
As increasingly complex, poorly water-soluble molecules enter development, AustinPx helps developers look beyond near-term ...
Robert Holt, PhD, associate director, Pharmaceutical Science, digiM Solution, discusses microstructure intelligence in more ...
The finalists for the 2026 CPHI Pharma Awards span15 categories including API development, digital transformation, ...
The FDA cleared four notable therapies within the same week in late August, spanning infectious disease, cardiometabolic care ...
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor. PhD, AbbVie, and Swita Singh, PhD, Bristol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results